story of the week
Givosiran for Acute Intermittent Porphyria
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
N. Engl. J. Med 2020 Jun 11;382(24)2289-2301, M Balwani, E Sardh, P Ventura, PA Peiró, DC Rees, U Stölzel, DM Bissell, HL Bonkovsky, J Windyga, KE Anderson, C Parker, SM Silver, SB Keel, JD Wang, PE Stein, P Harper, D Vassiliou, B Wang, J Phillips, A Ivanova, JG Langendonk, R Kauppinen, E Minder, Y Horie, C Penz, J Chen, S Liu, JJ Ko, MT Sweetser, P Garg, A Vaishnaw, JB Kim, AR Simon, L GouyaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.